The United Laboratories International Holdings ( (HK:3933) ) has shared an announcement.
The United Laboratories International Holdings Limited announced that its innovative drug, UBT251 Injection, has received FDA approval for phase II clinical trials targeting chronic kidney disease (CKD). This development marks a significant milestone as the company is the first in China and second worldwide to advance a long-acting triple agonist of GLP-1/GIP/GCG into clinical trials. The drug has shown superior efficacy in preclinical models compared to Semaglutide, potentially offering new treatment options for metabolism-related CKD. This approval enhances the company’s competitive edge in the biopharmaceutical industry and aligns with its commitment to advancing research and development.
More about The United Laboratories International Holdings
The United Laboratories International Holdings Limited is a biopharmaceutical company incorporated in the Cayman Islands. It focuses on the development of innovative drugs, particularly in the areas of chronic diseases such as type 2 diabetes mellitus (T2DM), obesity, and chronic kidney disease (CKD). The company is a pioneer in China and the second globally to conduct clinical trials for a long-acting triple agonist of GLP-1/GIP/GCG.
YTD Price Performance: 1.27%
Average Trading Volume: 1,100
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $3.07B
For an in-depth examination of 3933 stock, go to TipRanks’ Stock Analysis page.